Not applicableNot Yet RecruitingNCT07285408What this trial is testingSarcopenia and NMIBC Prognosis StudyWho this might be right forBladder Cancer Cell Transitional General Hospital Sveti Duh 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05943106What this trial is testingBCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsWho this might be right forNon-Muscle- Invasive Bladder Cancer AstraZeneca 100
Not applicableStudy completedNCT03664258What this trial is testingA Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)Who this might be right forNon-muscle-invasive Bladder Cancer Cepheid 852
Testing effectiveness (Phase 2)Ended earlyNCT03719300What this trial is testingCodex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBCWho this might be right forNon-muscle Invasive Bladder Cancer (NMIBC) Anchiano Therapeutics Israel Ltd. 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793What this trial is testingToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyWho this might be right forUrinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more First Affiliated Hospital of Wenzhou Medical University 106
Not applicableLooking for participantsNCT06991868What this trial is testingProspective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)Who this might be right forNMIBCMIBCUTUC Peking University First Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT07122414What this trial is testingIntravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder CancerWho this might be right forNon-muscle Invasive Bladder Cancer (NMIBC) Suzhou Forlong Biotechnology Co., Ltd 80
Testing effectiveness (Phase 2)Study completedNCT01697306What this trial is testingThe Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder CancerWho this might be right forBladder Cancer A.O.U. Città della Salute e della Scienza 120
Not applicableLooking for participantsNCT07187063What this trial is testingUsing Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder CancerWho this might be right forNon-muscle Invasive Bladder Cancer (NMIBC) Lahey Clinic 56
Large-scale testing (Phase 3)Ended earlyNCT02982395What this trial is testingStudy to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBCWho this might be right forNon Muscle Invasive Bladder Cancer Samyang Biopharmaceuticals Corporation 36
Testing effectiveness (Phase 2)Looking for participantsNCT06995677What this trial is testingEfficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerWho this might be right forLow-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more Tyra Biosciences, Inc 90
Large-scale testing (Phase 3)Study completedNCT05136898What this trial is testingFeasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)Who this might be right forBladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder UroGen Pharma Ltd. 8
Testing effectiveness (Phase 2)Study completedNCT03914794What this trial is testingPemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk TumorsWho this might be right forBladder CancerNMIBCNon-Muscle Invasive Bladder Cancer+1 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 30
Not applicableStudy completedNCT02891460What this trial is testingPilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC PatientsWho this might be right forUrinary Bladder NeoplasmsUrologic NeoplasmsNeoplasms+2 more UroGen Pharma Ltd. 18
Not applicableActive Not RecruitingNCT05671900What this trial is testingGemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder CancerWho this might be right forNon-muscle-invasive Bladder Cancer Clinical Hospital Centre Zagreb 70
Not applicableAvailableNCT06810141What this trial is testingResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerWho this might be right forNMIBC ImmunityBio, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05957757What this trial is testingRC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 ExpressionWho this might be right forNon-Muscle Invasive Bladder CancerHER2 RenJi Hospital 20
Large-scale testing (Phase 3)Ended earlyNCT01475266What this trial is testingSingle Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)Who this might be right forBladder Cancer Nippon Kayaku Co., Ltd. 51
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032What this trial is testingEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Who this might be right forHigh-risk Non-muscle Invasive Bladder Cancer Merck Sharp & Dohme LLC 1,397
Testing effectiveness (Phase 2)Study completedNCT02015104What this trial is testingStudy of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGWho this might be right forBladder Cancer National Cancer Institute (NCI) 32